Skip to content

The Efficacy and Safety of Pars Plana Filtration for the Management of Refractory Glaucoma

The Efficacy and Safety of Pars Plana Filtration for the Management of Refractory Glaucoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096655
Enrollment
Unknown
Registered
2025-01-27
Start date
2025-02-12
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Various types of glaucoma are difficult to treat and have uncertain prognoses due to complex causes, including: (1) Acute angle-closure

Interventions

Intervention group:Pars Plana Filtration

Sponsors

Eye Hospital, Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Participants must be at least 18 years old, of any gender, and provide informed consent; 2.Participants must have a confirmed diagnosis of refractory glaucoma, meet the criteria for anti-glaucoma surgery, and undergo pars plana filtration treatment; 3.Participants must willingly enroll in the study, provide informed consent, and demonstrate willingness to adhere to scheduled visits and related procedures;

Exclusion criteria

Exclusion criteria: 1.Patients who refuse to sign the informed consent document; 2.Patients unsuitable for pars plana filtration: a) Patients with severe scarring adhesions and difficult conjunctival tenon separation; b) Patients with severe scleral diseases such as scleritis and scleral ring stapling, which are generally not suitable for this procedure; c) Patients with severe vitreous hemorrhage and fibrosis, as well as patients with significant retinal detachment and other serious retinal lesions; 3.Patients with advanced heart and lung conditions and terminal cancer that prevent ophthalmic surgery; 4.Patients with acute infectious inflammation in the eye, posing an infection risk; 5.Pregnant or breastfeeding individuals; 6.Patients unable to complete at least one year of routine post-enrollment clinical follow-up; 7.Other patients deemed unsuitable for enrollment by the investigator.

Design outcomes

Primary

MeasureTime frame
Intraocular pressure;Surgical qualified success rate;

Secondary

MeasureTime frame
the number of anti-glaucoma medications;visual acuity;

Countries

China

Contacts

Public ContactYuanbo Liang

Eye Hospital, Wenzhou Medical University

yuanboliang@126.com+86 577 8805 3493

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026